DTIL - Precision BioSciences Inc logo

DTIL

Precision BioSciences Inc

Precision BioSciences develops in vivo gene editing therapies using its ARCUS platform, focusing on gene insertion, excision, and repair. Its products target conditions like chronic hepatitis B, Duchenne muscular dystrophy, and mitochondrial diseases.

⚕️ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago $21today

Score Overview

1 Year
Score
Net Growth-15.33%
Net TrendShrank
Net Income Consistency
Rev Growth31.49%
Rev TrendGrew
Revenue Consistency
5 Years
Score3.4
Net Growth-72.32%
Net Trend40%
Net Income Consistency
Rev Growth-61.00%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth43.22%
Net Trend43%
Net Income Consistency
Rev Growth102.60%
Rev Trend71%
Revenue Consistency

See the full market ranking →

Precision BioSciences Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 24M to $ 34M and net income went from -$ 109M to -$ 45M. Revenue increased in 3 of those 5 years; net income in 2.

Precision BioSciences Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.42
1 Year2025-08-12
$ 4.3869.41%
5 Years2021-08-12
$ 352.50-97.90%
All Time2019-03-28
$ 523.20-98.58%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 45M-$ 52M$ 87M
2025$ 34M-$ 45M$ 115M
2024$ 68M$ 7M$ 86M
2023$ 48M-$ 61M$ 116M
2022$ 25M-$ 111M$ 189M
2021$ 115M-$ 30M$ 143M
2020$ 24M-$ 109M$ 89M
IPO2019$ 22M-$ 92M$ 180M

Explore beyond DTIL

You're looking at Precision BioSciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies